Novartis announced on November 18, 2026, that it will present nearly 60 abstracts at the 2026 American Society of Hematology (ASH) meeting and San Antonio Breast Cancer Symposium (SABCS).
At ASH, a key focus is 144-week Phase III MANIFEST-2 follow-up:
investigational pelabresib plus ruxolitinib showed sustained clinical effects in first-line, JAK-inhibitor-naïve myelofibrosis. The program includes eight oral presentations featuring Novartis medicines.
At SABCS, a six-year NATALEE analysis will report ribociclib (Kisqali) outcomes by lymph-node status in HR-positive/HER2-negative early breast cancer, adding to long-term evidence for the treatment.
The company will also present the first clinical results for SNV4818, now called RAE346, a mutant-selective PI3Kα inhibitor acquired from Synnovation, in a Phase I/II study of PIK3CA-mutated advanced cancers, including breast cancer.
Overall, the announcement highlights both established products and investigational programs in hematology and breast cancer; the release previews conference presentations rather than reporting complete study results.
Sources:
Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS
Novartis data at ASH and SABCS showcase latest innovations in ...
Novartis data at ASH and SABCS show strength of pipeline ...
Novartis United States of America